Since high dose 5-Aza-CdR has potential risk of leukopenia or bone marrow hypoplasia [35], targeted delivery of concentrated 5-Aza-CdR via advanced drug delivery system may more efficiently recover ductal ANO1 expression with minimal systemic toxicity. The gene discussed is ANO1; the disease is Bone marrow hypocellularity.